Selkirk Pharma, Inc. has completed the Aseptic Process Simulation (APS) qualification of its sterile manufacturing facility, increasing its fill/finish capacity for injectable drugs, vaccines, and biological therapeutics. The purpose-built facility operates with advanced technology to ensure high quality and high yields, meeting Annex 1 compliance standards for European markets and the highest quality standards for U.S. markets. This development addresses industry bottlenecks and lack of U.S.-based manufacturing capacity, offering exceptional clinical and commercial manufacturing services for small molecule and biologics drug sponsors. The new facility will alleviate growing demands and capacity constraints within the fill/finish industry, providing qualified, reliable services to customers and their patients.
Source link
Selkirk Pharma announces new APS qualified facility with advanced fill/finish capacity in Spokane, WA
